Allogeneic hematopoietic stem cell transplantation (HSCT)

PROCEDURE3 trials

Sponsors

Sidney Kimmel Cancer Center at Thomas Jefferson University, Institute of Hematology & Blood Diseases Hospital, China

Conditions

AMLHematopoietic/Lymphoid CancerMalignant Neoplasm

Phase 2

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

TerminatedNCT01871441

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityMalignant Neoplasm

Start: 2013-05-17End: 2016-10-20Updated: 2025-05-16

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

CompletedNCT01982682

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHematopoietic/Lymphoid Cancer

Start: 2013-11-04End: 2017-03-27Updated: 2025-04-30

Unknown Phase

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

Not yet recruitingNCT07490288

Institute of Hematology & Blood Diseases Hospital, ChinaAML

Start: 2026-03-01End: 2029-03-01Target: 30Updated: 2026-03-24